ADMA Biologics
ADMA
13 hedge funds and large institutions have $66.8M invested in ADMA Biologics in 2014 Q4 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
+$41.3M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$10M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.84M |
| 4 |
BC
Broadfin Capital
New York
|
+$4.45M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$4.12M |
Top Sellers
ADMA Hedge Fund Activity: Q4 2014 in Review
13 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2014, worth a combined $66.8M.
Buyers outnumbered sellers: 13 funds opened new ADMA positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Aisling Capital, opening a new position worth an estimated $41.3M.
- 13 institutional investors held ADMA Biologics (ADMA) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $66.8M of ADMA Biologics stock for Q4 2014.
- 13 funds opened new ADMA Biologics positions in Q4 2014 and 0 closed out, a net change of +13 holders.
- The largest ADMA Biologics buyer in Q4 2014 was Aisling Capital, an estimated $41.3M added.
Based on aggregated 13F filings for Q4 2014.